In lung cancer, C-MYC is frequently dysregulated, important for cancer stem cell (CSC) properties, and associated with unfavorable patient survival [72], and its expression was significantly correlated with programmed death-ligand 1 (PD-L1) expression in NSCLC [73]. The gene discussed is MYC; the disease is lung carcinoma.